Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Work In Process (2016 - 2025)

Historic Work In Process for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Q3 2025 value amounting to $42.5 million.

  • Amphastar Pharmaceuticals' Work In Process rose 1788.93% to $42.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year increase of 1788.93%. This contributed to the annual value of $32.8 million for FY2024, which is 644.02% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Work In Process stood at $42.5 million, which was up 1788.93% from $43.6 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Work In Process' 5-year high stood at $43.8 million during Q1 2025, with a 5-year trough of $28.3 million in Q3 2023.
  • For the 5-year period, Amphastar Pharmaceuticals' Work In Process averaged around $36.3 million, with its median value being $36.0 million (2024).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Work In Process crashed by 2662.6% in 2023 and then skyrocketed by 3134.02% in 2025.
  • Amphastar Pharmaceuticals' Work In Process (Quarter) stood at $33.3 million in 2021, then increased by 11.39% to $37.1 million in 2022, then decreased by 16.9% to $30.8 million in 2023, then rose by 6.44% to $32.8 million in 2024, then increased by 29.42% to $42.5 million in 2025.
  • Its last three reported values are $42.5 million in Q3 2025, $43.6 million for Q2 2025, and $43.8 million during Q1 2025.